AKBA Q4 2020 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M-18.5% YoY

Gross Profit

$30M52.7% margin

Operating Income

-$85M-150.6% margin

Net Income

-$87M-153.4% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

-5.5%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$644M

Total Liabilities

$397M

Stockholders' Equity

$248M

Cash & Equivalents

$229M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$70M	-18.5%
Gross Profit	$30M	$60M	-49.8%
Operating Income	-$85M	-$95M	+10.0%
Net Income	-$87M	-$94M	+7.9%

Revenue Segments

Product

$35M61%

License Collaboration And Other Revenue

$22M39%